Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.

Published on Feb 18, 2021in European Journal of Nuclear Medicine and Molecular Imaging7.081
· DOI :10.1007/S00259-021-05233-2
R. Frood6
Estimated H-index: 6
(University of Leeds),
C. Burton (Leeds Teaching Hospitals NHS Trust)+ 4 AuthorsAndrew Scarsbrook8
Estimated H-index: 8
(University of Leeds)
Sources
Abstract
PURPOSE To systematically review the literature evaluating clinical utility of imaging metrics derived from baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for prediction of progression-free (PFS) and overall survival (OS) in patients with classical Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). METHODS A search of MEDLINE/PubMed, Web of Science, Cochrane, Scopus and clinicaltrials.gov databases was undertaken for articles evaluating PET/CT imaging metrics as outcome predictors in HL and DLBCL. PRISMA guidelines were followed. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool. RESULTS Forty-one articles were included (31 DLBCL, 10 HL). Significant predictive ability was reported in 5/20 DLBCL studies assessing SUVmax (PFS: HR 0.13-7.35, OS: HR 0.83-11.23), 17/19 assessing metabolic tumour volume (MTV) (PFS: HR 2.09-11.20, OS: HR 2.40-10.32) and 10/13 assessing total lesion glycolysis (TLG) (PFS: HR 1.078-11.21, OS: HR 2.40-4.82). Significant predictive ability was reported in 1/4 HL studies assessing SUVmax (HR not reported), 6/8 assessing MTV (PFS: HR 1.2-10.71, OS: HR 1.00-13.20) and 2/3 assessing TLG (HR not reported). There are 7/41 studies assessing the use of radiomics (4 DLBCL, 2 HL); 5/41 studies had internal validation and 2/41 included external validation. All studies had overall moderate or high risk of bias. CONCLUSION Most studies are retrospective, underpowered, heterogenous in their methodology and lack external validation of described models. Further work in protocol harmonisation, automated segmentation techniques and optimum performance cut-off is required to develop robust methodologies amenable for clinical utility.
References58
Newest
#1Nicolò Capobianco (Siemens)H-Index: 2
#2Michel MeignanH-Index: 52
Last. Irène Buvat (Université Paris-Saclay)H-Index: 46
view all 10 authors...
Total metabolic tumor volume (TMTV), calculated from 18F-labeled fluoro-2-deoxyglucose (18F-FDG) positron-emission tomography-computed tomography (PET/CT) baseline studies, is a prognostic factor in diffuse large B-cell lymphoma (DLBCL) whose measurement requires the segmentation of all malignant foci throughout the body. No consensus currently exists regarding the most accurate approach for such segmentation. Further, all methods still require extensive manual input from an experienced reader. ...
8 CitationsSource
#1Hajime SenjoH-Index: 3
#2Kenji Hirata (Hokkaido University)H-Index: 21
Last. Takanori TeshimaH-Index: 59
view all 11 authors...
Metabolic heterogeneity (MH) can be measured using 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the tra...
3 CitationsSource
#1Domenico Albano (University of Brescia)H-Index: 24
#2Angelica Mazzoletti (University of Brescia)H-Index: 3
Last. Francesco Bertagna (University of Brescia)H-Index: 27
view all 10 authors...
Elderly Hodgkin lymphoma (HL) is an aggressive lymphoma subgroup with high 18F-FDG avidity at 18F-FDG-PET/CT but no shared criteria for PET/CT in treatment evaluation and prediction of outcome are available. The aim of our bicentric study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in elderly HL. We retrospectively included 123 patients who underwent baseline 18F-FDG-PET/CT and end of treatment PET/CT scans. The PET images were...
6 CitationsSource
#1Laetitia VercellinoH-Index: 20
Last. Catherine Thieblemont (Sorbonne)H-Index: 82
view all 30 authors...
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase III REMARC study that randomized responding patients to RCHOP into maintenance lenalidomide or placebo. TMTV was comp...
12 CitationsSource
#1Nicolas Aide (UNICAEN: University of Caen Lower Normandy)H-Index: 28
#2Christophe FruchartH-Index: 27
Last. Charline Lasnon (French Institute of Health and Medical Research)H-Index: 12
view all 5 authors...
OBJECTIVES: To explore the prognostic value of positron emission tomography (PET) radiomic features in the field of diffuse large B cell lymphoma (DLBCL) treated with a first-line immunochemotherapy. METHODS: One-hundred thirty-two patients newly diagnosed with DLBCL were retrospectively included. PET studies were reconstructed using an ordered subset expectation maximisation algorithm with point spread function modelling. The total metabolic tumour volume (MTV) was recorded for each patient, an...
10 CitationsSource
#1Luca Ceriani (USI: University of Lugano)H-Index: 29
#2Giuseppe GrittiH-Index: 14
Last. Emanuele Zucca (USI: University of Lugano)H-Index: 83
view all 17 authors...
Several functional parameters from baseline (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography have been proposed as promising biomarkers of treatment efficacy in diffuse large B-cell lymphoma (DLBCL). We tested their ability to predict outcome in 2 cohorts of DLBCL patients receiving conventional immunochemotherapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP] regimen), either every 14 (R-CHOP14) or 21 days (R-...
8 CitationsSource
#1Anne-Ségolène Cottereau (Paris V: Paris Descartes University)H-Index: 14
#2Christophe Nioche (Université Paris-Saclay)H-Index: 15
Last. Irène Buvat (Université Paris-Saclay)H-Index: 46
view all 8 authors...
: We assessed the prognostic value of new radiomic features (RF) characterizing the lesion dissemination in baseline 18F-FDG PET and tested whether combining them with baseline metabolic tumour volume (MTV) could improve prediction of progression free survival (PFS) and overall survival (OS) in DLBCL patients. Methods: From the LNH073B trial (NCT00498043), patients with an advanced stage DLCBL and 18F-FDG PET/CT images available for review were selected. MTV and several RF, including the distanc...
16 CitationsSource
#1Coreline N. Burggraaff (VU: VU University Amsterdam)H-Index: 5
#2F. Rahman (Guy's and St Thomas' NHS Foundation Trust)H-Index: 11
Last. Ronald Boellaard (VU: VU University Amsterdam)H-Index: 83
view all 12 authors...
This pilot study aimed to determine interobserver reliability and ease of use of three workflows for measuring metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in diffuse large B cell lymphoma (DLBCL). Twelve baseline [18F]FDG PET/CT scans from DLBCL patients with wide variation in number and size of involved organs and lymph nodes were selected from the international PETRA consortium database. Three observers analyzed scans using three workflows. Workflow A: user-defined selection...
5 CitationsSource
#1Kun-Han Lue (NTHU: National Tsing Hua University)H-Index: 5
#2Yi-Feng WuH-Index: 3
Last. Yu-Hung ChenH-Index: 4
view all 7 authors...
PURPOSE: This study investigated whether a radiomic analysis of pretreatment F-FDG PET can predict prognosis in patients with Hodgkin lymphoma (HL). METHODS: Forty-two patients who were diagnosed as having HL and underwent pretreatment F-FDG PET scans were retrospectively enrolled. For each patient, we extracted 450 radiomic features from PET images. The prognostic significance of the clinical and radiomic features was assessed in relation to progression-free survival (PFS) and overall survival ...
12 CitationsSource
#1Yi‐Yang Zhang (PKU: Peking University)H-Index: 1
#2Le Song (PKU: Peking University)H-Index: 1
Last. Kai Hu (PKU: Peking University)H-Index: 1
view all 4 authors...
: In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R-CHOP-treated diffuse large B-cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of baseline and interim parameters for three-year progression-free survival (PFS), we conducted an analysis of 85 patients in China with DLBCL underwent baseline and interim PET/CT scans and treated at...
6 CitationsSource
Cited By0
Newest